Hexaell Biotech (Shanghai Weizhizhuo Biotechnology)
Company Details
About: Shanghai Weizhizhuo Biotechnology Co., Ltd. was established in 2015. It has production lines and R&D centers in the core area of Shanghai Jiading Industrial Park and Shanghai Zhangjiang High-tech Park. The company has internationally leading cell differentiation and production technology and is a new biomedical technology company focusing on severe liver diseases and cell therapy. The company's founders come from world-class academic research institutes and top pharmaceutical companies, and are committed to developing the world's most advanced innovative biomedical technologies and products to provide patients with better clinical solutions.
China is a country with a high incidence of liver disease, with 500,000 to 1 million new cases of liver failure each year, and the 28-day mortality rate of patients with acute liver failure is as high as 50%. The most effective treatment option at present is liver transplantation, but the high cost of treatment and the shortage of liver sources mean that only about 5,000 patients can undergo liver transplantation each year. In addition, the use of physical adsorption and plasma exchange cannot effectively remove toxins from the blood and promote the recovery of liver function.
The team led by Hui Lijian, a researcher at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, has collaborated with many institutions to break through the in vitro culture technology of "hepatocyte-like cells" and construct hiHep cells with the world-leading direct transdifferentiation technology. This technology also won the honor of "Top Ten Advances in Chinese Science" in 2011. With this as the core, Shanghai Weizhizhuo Biotechnology Co., Ltd., which has obtained the exclusive global license for this technology, has built a new HepaCure bioartificial liver support system, which provides a new and effective treatment for patients with liver failure caused by severe liver disease.
The HepaCure bioartificial liver is an in vitro liver function support system that can replace liver function in a short period of time, promote the recovery of autologous liver function in patients with liver failure, and buy time for patients planning liver transplantation to wait for a suitable liver source. It is like a small liver dialysis machine. During the dialysis process, it not only detoxifies the blood, but also supplies nutrients to the liver.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Hexaell Biotech (Shanghai Weizhizhuo Biotechnology) | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.